Skip to main content
TipRanks
Go Ultimate75% OFF

Aura Biosciences Inc (AURA) AI Stock Analysis

330 Followers
AURA

Aura Biosciences Inc

(NASDAQ:AURA)

Select Model
Rating:52Neutral
Price Target:$6.50â–¼(-8.58% Downside)
Action:reiterated
Date:11/10/26

The score is primarily held back by pre-revenue financials with widening losses and substantial ongoing cash burn, despite a low-debt balance sheet that supports near-term stability. Technicals are mixed/neutral without strong momentum, valuation signals are weak due to negative earnings and no dividend, and corporate events are modestly supportive due to Phase 3 progress but tempered by restructuring and rising expenses.

Positive Factors
Phase 3 executionCompleting enrollment in the pivotal CoMpass trial under a U.S. FDA Special Protocol Assessment is a meaningful development milestone. It advances bel-sar toward potentially registration-supporting data, provides a defined clinical path, and strengthens Aura’s position in frontline ocular oncology.
Negative Factors
Pre-revenue modelAura remains entirely dependent on clinical progress rather than product revenue, leaving no operating base to absorb research and corporate costs. Persistent and widening losses increase execution risk because the company must reach commercialization or obtain meaningful partnership revenue before building sustainable earnings power.

Aura Biosciences Inc (AURA) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%AURA+31.42%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$739.97M
Dividend Yield
―
Average Volume (3M)
900.47K
Price to Earnings (P/E)
-4.3
Beta (1Y)
1.52
Revenue Growth
―
EPS Growth
13.33%
Country
US
Employees
113
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aura Biosciences Inc Business Overview & Revenue Model

Company Description

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform...

Aura Biosciences Inc Financial Statement Overview

Summary

Financials reflect a development-stage biotech profile: no revenue and widening losses alongside heavy cash burn (negative operating/free cash flow in TTM). The main offset is a comparatively strong, low-leverage balance sheet with meaningful equity, which reduces near-term solvency risk but does not eliminate longer-term funding risk if burn persists.

Income Statement

18Very Negative

Balance Sheet

66Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000-1.29M00
EBITDA-141.29M-104.95M-85.58M-74.98M-57.59M-34.41M
Net Income-136.95M-106.19M-86.92M-76.41M-58.76M-35.25M
Balance Sheet
Total Assets321.62M169.43M182.50M255.07M223.94M160.03M
Cash, Cash Equivalents and Short-Term Investments297.23M144.24M151.09M226.15M188.81M149.06M
Total Debt16.17M17.38M18.77M19.56M20.86M975.00K
Total Liabilities34.19M32.52M30.53M29.23M28.35M7.71M
Stockholders Equity287.43M136.91M151.97M225.85M195.58M152.31M
Cash Flow
Free Cash Flow-109.68M-85.19M-81.06M-64.56M-55.70M-34.53M
Operating Cash Flow-109.30M-84.74M-79.81M-63.85M-54.60M-32.41M
Investing Cash Flow-141.20M35.59M68.82M-113.96M-67.87M-2.13M
Financing Cash Flow245.03M77.16M1.59M97.29M95.63M166.26M

Aura Biosciences Inc Technical Analysis

Technical Analysis SentimentPositive
Last Price7.11

Price Trends

50DMA6.54Positive
100DMA6.93Positive
200DMA6.79Positive

Market Momentum

MACD0.22Negative
RSI57.29Neutral
STOCH66.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Positive. The current price of 7.11 is above the 20-day moving average (MA) of 6.62, above the 50-day MA of 6.54, and above the 200-day MA of 6.79, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AURA.

Aura Biosciences Inc Risk Analysis

Aura Biosciences Inc disclosed 69 risk factors in its most recent earnings report. Aura Biosciences Inc reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.Q4, 2023
2.The FDA's agreement to a Special Protocol Assessment with respect to the study design of our global Phase 3 trial of bel-sar for the treatment of early-stage choroidal melanoma does not guarantee any particular outcome from regulatory review, including ultimate approval, and may not lead to a successful review or approval process.Q4, 2023

Aura Biosciences Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AURA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IRDIRD53Neutral$384.68M-2.609999.00%―-45.92%10.87%
AURAAURA52Neutral$739.97M-4.26-64.69%――13.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FDMTFDMT45Neutral$675.64M-4.38-47.06%―79952.50%29.07%
EYPTEYPT38Underperform$34.82M-0.08-168.83%―-93.91%-32.55%
OCSOCS38Underperform$471.63M-4.64-39.51%――31.72%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%AURAEYPTIRDFDMTOCSSGPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AURA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AURAAura Biosciences Inc7.111.6129.27%
EYPTEyepoint Pharma0.31-12.83-97.67%
IRDOpus Genetics, Inc.3.982.24128.74%
FDMT4D Molecular Therapeutics, Inc.12.231.2811.69%
OCSOculis Holding Ag7.64-11.51-60.10%
SGPSpyGlass Pharma32.886.4824.55%

Aura Biosciences Inc Corporate Events

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements

Aura Biosciences Reports Third-Quarter Results and Clinical Progress

Negative
Nov 9, 2026

On November 9, 2026, Aura reported third-quarter results for the period ended September 30 and updated its corporate presentation for investor and analyst meetings. Enrollment was complete in its Phase 3 CoMpass trial, with 108 participants having co...

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

Aura Biosciences Restructures, Refocuses on Ocular Oncology

Negative
Aug 11, 2026

Aura Biosciences reported second-quarter 2026 results on August 11, 2026, highlighting full enrollment of its Phase 3 CoMpass trial in early choroidal melanoma, with 108 patients and topline data expected in the second half of 2027. The trial, conduc...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026